Skip to content
sellModerate cluster of 510b5-1 plan

SAHA SAURABH sold $959k of CNTA

Chief Executive Officer at Centessa Pharmaceuticals plc. 55,000 shares at an average of $17.44, traded Dec 20, 2024, filed Dec 20, 2024.

Warning score
44
Value
$959k
55,000 shares
Holdings after
520,661
-10% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0001847903-24-000186, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 20, 2024SOpen-market sale
Ordinary Shares10b5-1
-55,000$17.44$959k520,661Dec 20, 2024

Related signals

Other insiders at Centessa Pharmaceuticals plc and this insider’s other filings.

ScoreSideCompanyInsiderValueSharesFiled
6Weaksell 510b5-1CNTA
Centessa Pharmaceuticals plc
Weinhoff Gregory M
Chief Business Officer
$170k10,000
14Weaksell 510b5-1CNTA
Centessa Pharmaceuticals plc
Anderson Karen M.
Chief People Officer
$284k16,500
18Weaksell 510b5-1CNTA
Centessa Pharmaceuticals plc
Bush Tia L
Chief Technology & Quality Ofc
$478k27,424
30Weaksell 510b5-1CNTA
Centessa Pharmaceuticals plc
HUSSAIN IQBAL J
General Counsel
$1.3M77,705
35Weaksell 510b5-1CNTA
Centessa Pharmaceuticals plc
SAHA SAURABH
Chief Executive Officer
$1.6M87,496
0Weaksell 210b5-1CNTA
Centessa Pharmaceuticals plc
Weinhoff Gregory M
Chief Business Officer
$177k10,000
0Weaksell 210b5-1CNTA
Centessa Pharmaceuticals plc
SAHA SAURABH
Chief Executive Officer
$5,451299
23Weaksell 210b5-1CNTA
Centessa Pharmaceuticals plc
SAHA SAURABH
Chief Executive Officer
$1.0M60,182
17Weaksell 210b5-1CNTA
Centessa Pharmaceuticals plc
SAHA SAURABH
Chief Executive Officer
$585k32,023
15Weaksell 210b5-1CNTA
Centessa Pharmaceuticals plc
Weinhoff Gregory M
Chief Business Officer
$181k11,742

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.